SAN ANTONIO - Investigators are reporting favorable results in a pilot neoadjuvant trial that tested a combination of lapatinib and nab-paclitaxel (AbraxaneR) for the treatment of HER2+ breast cancer. The findings were announced at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) by Virginia Kaklamani, MD, with Northwestern University in Chicago, Illinois...
More...
Hybrid Mode
